India, Sept. 14 -- Definium Therapeutics (DFTX) shares are gaining nearly 2% after the company announced positive topline results from the Phase 3 Panorama study of DT120 ODT in adults with generalized anxiety disorder.
The stock is currently trading at $39.57, up $0.68 or 1.75%, on the Nasdaq. It opened at $43.50 after closing the previous session at $38.89. The stock has traded between $8.77 and $49.70 over the past 52 weeks.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....